Injective rallies as Gulf Labs partnership and ETF proposals drive growth

Injective (INJ) has experienced significant market movement, with the token rising approximately 69% over a 30-day period to reach a price of $9.03. This growth coincides with the protocol reporting $3.58 million in annual revenue.

Key developments include a new partnership with Gulf Labs, which has joined the network as an institutional validator. This collaboration is expected to enhance network security, expand governance participation, and facilitate exploration into tokenization, stablecoins, and institutional on-chain finance.

In the United States, Injective Institutional Services registered as a transfer agent with the SEC in August. Additionally, Injective leadership recently met with officials from the White House, SEC, and Commodity Futures Trading Commission in Washington. While these meetings do not imply regulatory endorsement, they highlight the company's policy engagement. Furthermore, several exchange-traded fund (ETF) proposals have been filed by entities including 21Shares, Canary Capital, and REX-Osprey to provide U.S. investors with INJ exposure.